Table 1

Overview of head to head comparisons amongst GLP-1 analogues and DPP-4 inhibitors.

Study

Duration

Type

GLP-1 analogue

DPP-4 inhibitor

Co- existing therapy


DeFronzo et al. [31]

4 weeks

Double blind, double dummy, cross over

Exenatide 5 mcg twice daily for 1st week followed by 10 mcg twice daily for 2nd week

Sitagliptin 100 mg once daily

Metformin

Berg et al. [32]

8 weeks

Double blind, double dummy, cross over

Exenatide 10 mcg twice daily

Sitagliptin 100 mg once daily

none

1860-Lira DPP4 [33]

26 weeks

Open label parallel group

Liraglutide 1.2 mg and Liraglutide 1.8 mg

Sitagliptin 100 mg once daily

Metformin

DURATION 2 [35]

26 weeks

Double dummy

Exenatide QW 2 mg once weekly

Sitagliptin 100 mg once daily

Metformin

DURATION 4 [37]

26 weeks

Double dummy

Exenatide QW 2 mg once weekly

Sitagliptin 100 mg once daily

none

T-emerge 4 [39]

24 weeks

Double dummy

Taspoglutide 10 mg and 20 mg weekly

Sitagliptin 100 mg once daily

Metformin

1860- Lira DPP4 extension [34]

52 weeks

Open label parallel group

Exenatide 10 mcg twice daily

Sitagliptin 100 mg once daily

Metformin


DDP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1

Nisal et al. BMC Medicine 2012 10:152   doi:10.1186/1741-7015-10-152

Open Data